Updated:
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH is a Vienna-based biopharmaceutical firm focused on antibiotic R&D, developed lefamulin for CABP.
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH was founded in Vienna as a biopharmaceutical company targeting multi-drug resistant bacterial infections. Its lead candidate, lefamulin, received FDA approval in 2019 for community-acquired bacterial pneumonia (CABP), making it the first new antibiotic class in decades (per FDA, 2019). The firm's strategy centered on antibiotic development, a high-risk, low-return segment that few pharma companies pursue. Post-take-private in 2023, Nabriva shifted from a public biotech to a private asset-focused entity, likely funded by healthcare-dedicated investors. The firm's geographic footprint remains anchored in Europe, with regulatory filings in the US. Team size is not publicly disclosed, and the firm operates without a visible advisory board. No additional offices or philanthropic vehicles have been identified. The take-private in 2023 represents the most recent operational event (per SEC filings, 2023). Nabriva's structural differentiator is its focus on antibiotic R&D — a field with thin margins and high regulatory hurdles that few private entities sustain. Its post-take-private status allows it to avoid quarterly earnings pressure while advancing its pipeline.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Austria
City
Vienna
Corporate office
Vienna, Austria
Sector focus
Frequently asked questions
What does Nabriva Therapeutics GmbH do?
Nabriva develops novel antibiotics for multi-drug resistant infections. Its lead drug lefamulin (Xenleta) was FDA-approved in 2019 for community-acquired bacterial pneumonia (per FDA, 2019). The firm was publicly traded until a take-private in 2023.
Is Nabriva publicly traded or privately held?
As of 2023, Nabriva is privately held following a take-private transaction (per SEC filings, 2023). It previously traded on the NASDAQ under the ticker NBRV.
Where is Nabriva Therapeutics headquartered?
The firm's headquarters is in Vienna, Austria. Its R&D and clinical operations have historically been based there.
What investment stage does Nabriva target?
Nabriva focuses on late-stage clinical development and commercialization of antibiotic candidates. Its pipeline addresses critical bacterial infections, a niche with high medical need.
Who are the current owners or backers of Nabriva?
Publicly available information does not name specific owners or backers post-take-private. Likely healthcare-focused investors or a consortium acquired the firm (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: